Tempo reale stimato Cboe BZX  -  14:26 05/07/2022
179.15 USD   -0.21%
29/06L'unità di Johnson & Johnson ha ottenuto dalla FDA la designazione di terapia innovativa per il talquetamab nel mieloma multiplo.
24/06Janssen, di Johnson & Johnson, riceve l'approvazione del gruppo di esperti dell'Agenzia europea per i medicinali per un farmaco contro la leucemia.
24/06L'unità Janssen di Johnson & Johnson afferma che il comitato dell'EMA sostiene l'approvazione di Imbruvica per il trattamento della leucemia linfocitica cronica
RiassuntoTutte le notizieRaccomandazione analistiAltre lingueComunicati stampaPubblicazioni ufficialiNotizie del settore
Notizie in altre lingue su JOHNSON & JOHNSON
09:49INDICES: ni Value, ni Growth, Défensif !
01/07DOJ Says J&J Talc Bankruptcy Violates Congressional Mass Tort Rules
01/07Pharmaceutical companies still have the upper hand
30/06FDA bittet Impfstoffhersteller um Anpassung auf Omikron-Sublinien
30/06Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for..
30/06Hywin Holdings, FactSet Launch Global Health Care Index
29/06NHIF, Janssen Kenya Sign MOU to Enhance Prostrate Cancer Drugs Access
29/06Johnson & Johnson Unit Secures FDA's Breakthrough Therapy Designation For Talquetamab i..
29/06Estas empresas respetan el derecho al aborto en EE.UU.
29/06Ces sociétés respectent le droit à l'avortement aux États-Unis
28/06MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Li..
27/06Janssen Receives Positive CHMP Opinion for IMBRUVICA (ibrutinib) in a Fixed-Duration Co..
24/06Johnson & Johnson's Janssen Receives EU Medicines Agency Panel's Backing for Leukemia D..
24/06J&J: avis favorable de l'UE pour un anti-leucémique
24/06Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Tr..
24/06JOHNSON & JOHNSON'S JANSSEN: CHMP Backs Expanded Imbruvica Use in Chronic Lymphocytic Leu..
24/06J&J: confirme son engagement contre les maladies tropicales
23/06JOHNSON & JOHNSON: Renews Commitment to Fight Neglected Tropical Diseases, Investing in B..
22/06Powell's tall order to reassure investors
22/06ANALYST RECOMMENDATIONS: Johnson & Johnson, NatWest, Home Depot, Kraft Heinz, Vodafone...
21/06Le roi des céréales Kellogg annonce sa scission en trois entreprises
21/06TRANSCRIPT: Johnson & Johnson - Special Call
21/06Johnson & Johnson Opens Asia-Pacific Satellite Center for Global Health Discovery in Si..
21/06Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci..
21/06Johnson & Johnson Opens First Satellite Center for Global Health Discovery in Asia Paci..
18/06AFRIQUE DU SUD: une "bataille difficile" remportée avec la levée des brevets
17/06Standard & Poor's 500 Enters Bear Market Territory as Fed Pivot to Price Stability Fuel..
16/06Wall Street finit en forte baisse, craint que la Fed n'ait la main trop lourde
16/06TRANSCRIPT: Johnson & Johnson Presents at Goldman Sachs 43rd Annual Global Healthcare Con..
16/06Federal Government Removes Vaccination Requirements For Domestic And Out-Bound Travel
15/06Top Local Changemakers Addressing Health Equity Gaps Across the U.S. Named Johnson & Jo..
15/06Evotec enters a drug discovery collaboration with Janssen
15/06INSIDER SELL: Johnson & Johnson
14/06Evotec, Johnson & Johnson's Unit Janssen Partner to Discover New Drug Candidates
14/06Evotec kooperiert bei Wirkstoffforschung mit Janssen
13/06Valneva risque de ne pas fournir son vaccin à l'Europe
10/06Johnson & Johnson Unit Janssen Says Early Trial Data Shows Positive Results for Teclist..
10/06JOHNSON & JOHNSON: New IMBRUVICA® (ibrutinib) Data in Fixed-Duration Combination Regimen ..
10/06JOHNSON & JOHNSON: Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bisp..
10/06Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
10/06Genmab Seeks $405 Million in New Arbitration With Janssen
10/06Genmab Opens New Arbitration In Daratumumab License Dispute With Janssen
08/06COVID-19 VACCINES: No Sharing Of Know-How
08/06Johnson & Johnson Releases 2021 Health for Humanity Report Highlighting Performance on ..
08/06Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA (erdafitinib..
08/06Royal Philips - Willem Appelo to succeed Sophie Bechu as Philips Chief Operations Offic..
07/06Johnson & Johnson Unit Janssen Says Initial Data From Phase 2 Trial of Balversa Shows R..
07/06Philips Names Willem Appelo COO
06/06Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti..
06/06SECTOR UPDATE: Health Care Stocks Slip Amid Losses for Biotechs
06/06Emergent Biosolutions Claims Janssen Pharmaceuticals Breached COVID-19 Vaccine Producti..
06/06SECTOR UPDATE: Health Care Stocks Edging Higher This Afternoon
06/06SECTOR UPDATE: Health Care
06/06US Stocks Weakening in Midday Trading but Largely Staying on Positive Ground
06/06Top Midday Gainers
06/06Yumanity Therapeutics Shares Soar on Kineta Deal
06/06J&J Risks Up to $420 Million Liability as Emergent Claims COVID-19 Jab Contract Breach
06/06Wall Street Set for Gains, China Tech ADRs Rise on Signs of Easing Regulatory Pressure
06/06J&J: résultats encourageants dans le myélome multiple
06/06Emergent BioSolutions Says Janssen Has Breached Covid Vaccine Contract
06/06The Janssen Pharmaceutical - Phase 3 SHINE Results Show IMBRUVICA (ibrutinib)-Based Com..
06/06The Janssen Pharmaceutical Companies - Longer-term Data from CARTITUDE-1 Study Demonstr..
06/06The Janssen Pharmaceutical Companies - Updated Data for Janssen's Bispecific Teclistama..
06/06Top Premarket Gainers
06/06Yumanity to Sell Neurosciences Candidates, Merge With Kineta
06/06J&J: données mises à jour sur le teclistamab
06/06Johnson & Johnson agreed to acquire Assets of Wholesale Brokerage & Binding and Managin..
05/06JOHNSON & JOHNSON: Longer-term Data from CARTITUDE-1 Study Demonstrate Continued Deep and..
03/06Johnson & Johnson's Imbruvica Meets Target in Late-Stage Mantle Cell Lymphoma Trial in ..
03/06JOHNSON & JOHNSON: Phase 3 SHINE Results Show IMBRUVICA® (ibrutinib)-Based Combination Re..
02/06Bristol Myers, J&J Arthritis Drugs Cut Covid-19 Deaths in NIH Study
02/06The Janssen Pharmaceutical - New Data Show Patients Treated with First-in-Class TREMFYA..
01/06J&J: nouvelles données positives autour du Tremfya
1  2  3  4  5  6  7  8  9  10Succ.
Pubblicazioni ufficiali
Prossimo evento su JOHNSON & JOHNSON